Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the ICONA Foundation Cohort.

In the past years, NRTI backbone based on tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) has represented the standard of care in the antiretroviral setting. Increasing concerns about TDF renal and bone toxicity and availability of effective and safe alternatives, as abacavir (ABC), tenofovir alafenamide (TAF) or NRTI-sparing less-drug regimens (LDRs), enhances chances of TDF substitution. Rate and predictors of TDF discontinuation may have public health implications in the view of availability of TDF/FTC generic formulation.